Preferred Label : CDK4/6 Inhibitor BPI-1178;
NCIt definition : An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types
4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration,
CDK4/6 inhibitor BPI-1178 selectively targets and inhibits CDK4 and CDK6, which inhibits
the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents
CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses
DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine
kinases that are upregulated in many tumor cell types and play a key role in the regulation
of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.
BPI-1178 may be able to penetrate through the blood-brain barrier (BBB).;
Molecule name : BP I1178; BP-I1178;
NCI Metathesaurus CUI : CL1413419;
Origin ID : C175972;
UMLS CUI : C5446897;
Semantic type(s)
- concept_is_in_subset
- has_target
